O tratamento das reações na hanseníase
DOI:
https://doi.org/10.47878/hi.2000.v25.35369Resumo
.
Downloads
Não há dados estatísticos.
Referências
1. CHIN-A-LIEN, R.A.M., FABER, W. R. and NAAFS, B. Cyclosporine A treatment in reversal reaction. Trop. Geogr. Med. v.46, p.123-124, (1994).
2. ELY, H. Is pentoxifyline the drug of the decade? J Am Acad Dermatol 1994; 30: 639-642.
3. JACOBSON, J.M. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. The New England Journal of Medicine, v.336, n.21, p.1487-93, May, 1997.
4. MANANDHAR, R., LEMASTER, J.W., ROCHE, P.W. Risk Factors for Erythema Nodosum Leprosum. Int. J. Leprosy, v.67, n.3, p.270-278, September, 1999.
5. MARRIOT, J.B. Thalidomide as na emerging immunotherapeutic agent. Immunology Today, v.20, n.12, p.538-50, December, 1999.
6. MILLER, R.A. et al. Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohis-tologic remission. Int. J. Leprosy, v.55, n.3, p.441-9, September, 1987.
7. MOREIRA, A.L., et al. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL (Letter). Int. J. Leprosy, v.66, n.1, p.62-64, March, 1998.
8. NAAFS, B. Treatment of reactions and nerve damage. Int. J. Leprosy, v.64, n.4, p.S21-S28, 1996. Supplement.
9. SAMLASKA, C. P., WINFIELD, E.A. Pentoxifylline. J Am Acad Dermatol 1994; 30: 603-621
10. SAMPAIO, E.P. et al. The influence of thalidomide on the clinical and immunological manifestation of erythema nodosum leprosum. J. Infect. Dis. 168 (1993) 408-414.
11. SAMPAIO, E. P et al. Thalidomide selectively inhibits tumor necrosis factor-a production by stimulated human monoc-ytes. J. Exp. Med.173 (1991) 699-703.
12. SAMPAIO, E.P. et al. Pentoxifyline decreases in vivo and in vitro tumour necrosis factor-alpha (TNFa) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin. Exp. Immunol., v.111, n.2, p.300-308, February 1998.
13. SARNO, E.N. et al. Is pentoxifylline a viable alternative in the treatment of ENL? (Letter). Int. J. Leprosy.,v.63, n.4, p.570-1, December, 1995.
14. SARNO, E.N., GRAU, G. E., VIERRA, L. M. M. and NERY, J. A.C. Serum levels of tumor necrosis factor-alpha and interleukine 1 beta during leprosy reactional states. Clin. Exp. lmmunol. v.84, p.103-108, (1991).
15. TALHARI, S. et al. Pentoxifylline maybe useful in the treatment of type 2 leprosy reactions (Letter). Leprosy Rev., v.66, n.1, p.261263, March, 1995.
16. TENTH INTERNATIONAL LEPROSY CONGRESS, Bergen, 1973. Therapy - Commitee 6.
17. UYEMURA, K. et al. Effect of cyclosporine A in erythema nodosum leprosum. J. Immunol., v.137, n.11, p.3620-3, December, 1986.
18. VAN GOMPEL, A. et al. Cyclosporin A is not very effective in erythema nodosum leprosum (ENL). Trop. Geogr. Med., v.46, n.5, p.123-4, 1994.
19. VIDES, LA. et al. Effect of zafirlukast on leprosy reaction (Letter). Int. J. Leprosy, v.67, n.1, p.71-74, March, 1999.
20. WELSH, O. et al. A new therapeutic approach to type II leprosy reaction. Int. J. Derm., v.38, 12, p.931-833, December, 1999.
2. ELY, H. Is pentoxifyline the drug of the decade? J Am Acad Dermatol 1994; 30: 639-642.
3. JACOBSON, J.M. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. The New England Journal of Medicine, v.336, n.21, p.1487-93, May, 1997.
4. MANANDHAR, R., LEMASTER, J.W., ROCHE, P.W. Risk Factors for Erythema Nodosum Leprosum. Int. J. Leprosy, v.67, n.3, p.270-278, September, 1999.
5. MARRIOT, J.B. Thalidomide as na emerging immunotherapeutic agent. Immunology Today, v.20, n.12, p.538-50, December, 1999.
6. MILLER, R.A. et al. Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohis-tologic remission. Int. J. Leprosy, v.55, n.3, p.441-9, September, 1987.
7. MOREIRA, A.L., et al. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL (Letter). Int. J. Leprosy, v.66, n.1, p.62-64, March, 1998.
8. NAAFS, B. Treatment of reactions and nerve damage. Int. J. Leprosy, v.64, n.4, p.S21-S28, 1996. Supplement.
9. SAMLASKA, C. P., WINFIELD, E.A. Pentoxifylline. J Am Acad Dermatol 1994; 30: 603-621
10. SAMPAIO, E.P. et al. The influence of thalidomide on the clinical and immunological manifestation of erythema nodosum leprosum. J. Infect. Dis. 168 (1993) 408-414.
11. SAMPAIO, E. P et al. Thalidomide selectively inhibits tumor necrosis factor-a production by stimulated human monoc-ytes. J. Exp. Med.173 (1991) 699-703.
12. SAMPAIO, E.P. et al. Pentoxifyline decreases in vivo and in vitro tumour necrosis factor-alpha (TNFa) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin. Exp. Immunol., v.111, n.2, p.300-308, February 1998.
13. SARNO, E.N. et al. Is pentoxifylline a viable alternative in the treatment of ENL? (Letter). Int. J. Leprosy.,v.63, n.4, p.570-1, December, 1995.
14. SARNO, E.N., GRAU, G. E., VIERRA, L. M. M. and NERY, J. A.C. Serum levels of tumor necrosis factor-alpha and interleukine 1 beta during leprosy reactional states. Clin. Exp. lmmunol. v.84, p.103-108, (1991).
15. TALHARI, S. et al. Pentoxifylline maybe useful in the treatment of type 2 leprosy reactions (Letter). Leprosy Rev., v.66, n.1, p.261263, March, 1995.
16. TENTH INTERNATIONAL LEPROSY CONGRESS, Bergen, 1973. Therapy - Commitee 6.
17. UYEMURA, K. et al. Effect of cyclosporine A in erythema nodosum leprosum. J. Immunol., v.137, n.11, p.3620-3, December, 1986.
18. VAN GOMPEL, A. et al. Cyclosporin A is not very effective in erythema nodosum leprosum (ENL). Trop. Geogr. Med., v.46, n.5, p.123-4, 1994.
19. VIDES, LA. et al. Effect of zafirlukast on leprosy reaction (Letter). Int. J. Leprosy, v.67, n.1, p.71-74, March, 1999.
20. WELSH, O. et al. A new therapeutic approach to type II leprosy reaction. Int. J. Derm., v.38, 12, p.931-833, December, 1999.
Downloads
Publicado
30-06-2000
Como Citar
1.
Opromolla D. O tratamento das reações na hanseníase. Hansen. Int. [Internet]. 30º de junho de 2000 [citado 25º de abril de 2024];25(1):1-3. Disponível em: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35369
Edição
Seção
Editorial
Licença
Este periódico está licenciado sob uma Creative Commons Attribution 4.0 International License.
